SphK2 deficiency abrogated HFHSD-induced body weight gain, hyperlipidemia, hepatic inflammation and fibrosis (Figs. 1 and 2), resulting in a tumor-suppressive microenvironment. Here, SPHK2 is linked to hyperlipidemia.